BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32134806)

  • 1. Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study.
    Xie T; Liu Y; Zhang Z; Zhang X; Gong J; Qi C; Li J; Shen L; Peng Z
    J Immunother; 2020 May; 43(4):139-144. PubMed ID: 32134806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
    Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.
    Yee EJ; Gilbert D; Kaplan J; van Dyk L; Kim SS; Berg L; Clambey E; Wani S; McCarter MD; Stewart CL
    J Surg Res; 2024 Apr; 296():742-750. PubMed ID: 38368775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
    Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
    Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
    Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
    J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and characteristics of Epstein-Barr virus associated gastric carcinoma in Gansu Province, Northwest China with mRNA expression of glycoprotein BMRF2.
    Guo C; Wei J; Scott RS; Chen Y; Chen Z; Zhao W; Zhang C; Wang B; Chai C; Dai G; Li M; Zhang F
    J Med Virol; 2020 Mar; 92(3):356-363. PubMed ID: 31663617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
    Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
    BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer.
    Shoda K; Ichikawa D; Fujita Y; Masuda K; Hiramoto H; Hamada J; Arita T; Konishi H; Kosuga T; Komatsu S; Shiozaki A; Okamoto K; Imoto I; Otsuji E
    Oncotarget; 2017 Apr; 8(17):28796-28804. PubMed ID: 28430637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtraction of Epstein-Barr virus and microsatellite instability genotypes from the Lauren histotypes: Combined molecular and histologic subtyping with clinicopathological and prognostic significance validated in a cohort of 1,248 cases.
    Huang SC; Ng KF; Yeh TS; Cheng CT; Lin JS; Liu YJ; Chuang HC; Chen TC
    Int J Cancer; 2019 Dec; 145(12):3218-3230. PubMed ID: 30771224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
    Kim EJ; Chae H; Park YS; Ryu MH; Kim HD; Shin J; Park YS; Moon MS; Kang YK
    Gastric Cancer; 2024 Jan; 27(1):146-154. PubMed ID: 38006567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia in Epstein-Barr virus-associated and Epstein-Barr virus-negative gastric cancer.
    Zhang Y; Chen JN; Dong M; Zhang ZG; Zhang YW; Wu JY; Du H; Li HG; Huang Y; Shao CK
    Hum Pathol; 2017 May; 63():128-138. PubMed ID: 28300576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
    Dong M; Wang HY; Zhao XX; Chen JN; Zhang YW; Huang Y; Xue L; Li HG; Du H; Wu XY; Shao CK
    Hum Pathol; 2016 Jul; 53():25-34. PubMed ID: 26980034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
    Masetti M; Lindinger M; Lorenzen S
    Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Epstein-Barr virus and its encoded proteins with Helicobacter pylori and expression of c-met and c-myc in gastric carcinoma.
    Luo B; Wang Y; Wang XF; Gao Y; Huang BH; Zhao P
    World J Gastroenterol; 2006 Mar; 12(12):1842-8. PubMed ID: 16609989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outlooks on Epstein-Barr virus associated gastric cancer.
    Naseem M; Barzi A; Brezden-Masley C; Puccini A; Berger MD; Tokunaga R; Battaglin F; Soni S; McSkane M; Zhang W; Lenz HJ
    Cancer Treat Rev; 2018 May; 66():15-22. PubMed ID: 29631196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report.
    An G; He XC; Bai J; Wang J
    Medicine (Baltimore); 2023 Mar; 102(13):e33377. PubMed ID: 37000076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma.
    Choi SJ; Shin YS; Kang BW; Kim JG; Won KJ; Lieberman PM; Cho H; Kang H
    Arch Pharm Res; 2017 Aug; 40(8):894-905. PubMed ID: 28779374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal.
    Ribeiro J; Oliveira A; Malta M; Oliveira C; Silva F; Galaghar A; Afonso LP; Neves MC; Medeiros R; Pimentel-Nunes P; Sousa H
    World J Gastroenterol; 2017 Oct; 23(40):7292-7302. PubMed ID: 29142476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.